Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
JAMA|September 6, 2017
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingDiana Mandelker, Liying Zhang, Yelena Kemel, et al.
Nature Communications|November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Genetics|January 16, 2019
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert M Samstein, Chung-Han Lee, Alexander N Shoushtari, et al.
European Urology|May 20, 2023
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational InsightsStella Koutros, Lambertus A Kiemeney, Parichoy Pal Choudhury, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2022
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II TrialSamuel A Funt, Michael Lattanzi, Karissa Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2019
Cancer Susceptibility Mutations in Patients With Urothelial MalignanciesMaria I Carlo, Vignesh Ravichandran, Preethi Srinavasan, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.
Lancet (London, England)|December 13, 2016
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
JAMA|September 6, 2017
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingDiana Mandelker, Liying Zhang, Yelena Kemel, et al.
Nature Communications|November 3, 2022
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiationJoshua I Warrick, Wenhuo Hu, Hironobu Yamashita, et al.
Nature Genetics|January 16, 2019
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert M Samstein, Chung-Han Lee, Alexander N Shoushtari, et al.
European Urology|May 20, 2023
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational InsightsStella Koutros, Lambertus A Kiemeney, Parichoy Pal Choudhury, et al.
Pageof 17